There’s a new kid on the block. The Beijing Genomics Institute revealed a new NextGen Sequencer, Revolocity, based on technology derived from its subsidiary Complete Genomics. The new instrument is designed for human whole genome and human exome sequencing, claiming to sequence up to 10,000 human genomes per year at 50X coverage in less than 8 days per genome. The cost of the instrument is around $10M. The platform uses DNA nanoball technology, in contrast to Ion semiconductor sequencing, Illumina sequencing by synthesis, and PacBio single molecule methods. Revolocity is a short-read instrument with 25bp paired-end reads and 300bp inserts, so a total read length around 350bp. Revolocity is clearly a highly specialized sequencer targeted only at human genome sequencing. With the high price tag and focus on humans, it will obviously have limited market share. We’ll see what impact it has on the DNA sequencing community in coming months.